Study: Metformin/rosiglitazone combo may delay type 2 diabetes

07/10/2011 | HealthDay News

A low-dose metformin/rosiglitazone treatment fared better than a placebo in improving glycemic control and insulin sensitivity in participants with impaired glucose tolerance, a study in Diabetes Care found. However, the treatment did not reduce the risk of insulin resistance and beta cell dysfunction that develop over time, experts said. The findings suggest that metformin/rosiglitazone therapy may help delay the early onset of type 2 diabetes, but not its succeeding complications, researchers added.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN